Please ensure Javascript is enabled for purposes of website accessibility

Why Neurocrine Biosciences Stock Is Soaring Higher Today

By George Budwell - Apr 12, 2017 at 12:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech struck regulatory gold with its tardive dyskinesia drug, Ingrezza.

What happened

Shares of the mid-cap biotech Neurocrine Biosciences (NBIX 1.19%) rocketed higher today as a result of the Food and Drug Administration (FDA) approving the company's first drug, Ingrezza, as a treatment for adults with tardive dyskinesia (TD). Tardive dyskinesia is a movement disorder involving the tongue, lips, face, trunk, and extremities in patients treated with anti-psychotic medications for long periods of time. The drugmaker's shares were up by 23% as of 11:45 a.m. EDT on the back of this positive regulatory news. 

Positive trending chart.

Image source: Getty Images.

So what

Ingrezza is the first drug approved in the U.S. for this rare but debilitating movement disorder. So, from a value-creation standpoint, this first-mover advantage may be worth upwards of $1 billion in peak sales, according to some analysts.  

Now what

Neurocrine isn't wasting any time in getting Ingrezza's commercial launch underway. The company plans to have the drug in the distribution channel by next week through a select pharmacy network. And Ingrezza's broader promotion will reportedly start on May 1.

The one potential hiccup in Ingrezza's commercialization, though, may be the entry of Teva Pharmaceutical Industries(TEVA 1.46%) rival drug, Austedo. Teva's Austedo is currently under priority review with the FDA, with the agency assigning the drug a Prescription Drug User Fee Act target action date of Aug. 30. So, Austedo could be on the market for TD before the end of 2017.

The good news is that the FDA blessed Ingrezza with a fairly clean label, whereas Austedo already carries a black-box warning for depression when used as a treatment for Huntington's chorea. In other words, Ingrezza should ultimately garner both a first-mover and best-in-class advantage over Teva's drug.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Neurocrine Biosciences, Inc. Stock Quote
Neurocrine Biosciences, Inc.
$98.64 (1.19%) $1.16
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
$7.63 (1.46%) $0.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/01/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.